

Saeed A. Jortani, Ph.D.
1004 Woodland Ridge Court
Louisville, KY 40245
502-852-8835 Tel Office
502-852-7674 Fax Office
502-552-5753 Cell
sjortani@louisville.edu

EDUCATION

- 1993 - 1996 Clinical Chemistry Fellow, Department of Pathology, School of Medicine, University of Louisville, Louisville, Kentucky
- 1993 Doctor of Philosophy, Clinical Pathology, Medical College of Virginia, Richmond, Virginia **Thesis Title:** Stereoselective Metabolism and Disposition of Thioridazine Enantiomers
- 1988 B.S. (Honors) Biology, Virginia Commonwealth University, Richmond, Virginia

ACADEMIC APPOINTMENTS

- 2007 – Present Associate Professor, Department of Pathology and Laboratory Medicine, School of Medicine, University of Louisville, Louisville, Kentucky.
- 2001 – Present Director, Forensic Toxicology Program, Department of Pathology and Laboratory Medicine, School of Medicine, University of Louisville, Louisville, Kentucky.
- 2003 – Present Director of Clinical Toxicology, University of Louisville Hospital. Louisville, Kentucky.
- 2001 – Present Director, Forensic Toxicology Program, Department of Pathology and Laboratory Medicine, School of Medicine, University of Louisville, Louisville, Kentucky.
- 2003 – Present Director of Clinical Toxicology, University of Louisville Hospital. Louisville, Kentucky.
- 2001 – 2007 Assistant Professor, Department of Pathology and Laboratory Medicine, School of Medicine, University of Louisville, Louisville, Kentucky.
- 2001 – 2007 Assistant Professor, Department of Pathology and Laboratory Medicine, School of Medicine, University of Louisville, Louisville, Kentucky.
- 1999 - 2008 Associate Director, Diagnostic Reference Laboratory, Department of Pathology and Laboratory Medicine, School of Medicine, University of Louisville, Louisville, Kentucky.
- 1997 - 1999 Assistant Director, Diagnostic Reference Laboratory, Department of

Update: April 2010

Pathology and Laboratory Medicine, School of Medicine, University of Louisville, Louisville, Kentucky

- 1995 - 1997 Manager, Digitalis Reference Laboratory, Department of Pathology, School of Medicine, University of Louisville, Louisville, Kentucky
- 1988 - 1993 Student Research Manager, Department of Pharmacology & Toxicology, Medical College of Virginia, Richmond, Virginia
- 1987-1988 Laboratory Specialist (A), Department of Pharmacology & Toxicology, Medical College of Virginia, Richmond, Virginia
- 1985-1987 Research Assistant, Department of Pharmacology & Toxicology, Medical College of Virginia, Richmond, Virginia

CERTIFICATION

- 1998 Diplomate, American Board for Clinical Chemistry
1998 Fellow, National Academy of Clinical Biochemistry

MEMBERSHIPS

- American Association for Clinical Chemistry (AACC) - MEMBER
Society of Forensic Toxicologists (SOFT) - MEMBER
International Congress of Therapeutic Drug Monitoring and Clinical Toxicology - MEMBER
National Academy for Clinical Biochemistry – FELLOW
American Heart Association - MEMBER
Institute for Molecular Diversity and Drug Design (U of L) - MEMBER
Center for Genetic and Molecular Medicine (U of L) - MEMBER
NIEHS Center for Environmental Genomics and Integrative Biology (CEGIB) – MEMBER
American Academy of Forensic Sciences 1990-1993

AWARDS AND HONORS

- 2005 Winner, AACC's Best Abstract Award for the Industry Division
2004 Winner, Arnold Katchman Award, Ohio Valley Section of AACC
2004 Outstanding Research Faculty, Dept. of Pathology and lab Med, U of L
2003 Young Investigator Award, Therapeutic Drug Monitoring and Clinical Toxicology Division of the AACC
1997 Winner, Grafton Chase Award (Clinical Ligand Assay Society)
1995 First Place Poster Contest Winner. AACC in Anaheim, California.
1989 The Honor Society of Phi Kappa Phi
1988 Phi Sigma (Biology Honor Society)
1989 Phi Sigma Undergraduate Research Award
1989 Sigma Zeta (Honorary Science Society)
1988 VCU Dean's list
1988 & 1989 National Honors Dean's List
1987 - 1988 VCU Honors Program
1986 Phi Eta Sigma (Freshman National Honors Society)

COMMITTEES

2009 – Present	Commissioner, the Commission on Accreditation in Clinical Chemistry
2009 – Present	Chair, AACC Proteomics Division
2008 – Present	Member-at-large, Executive Board TDM –Toxicology division of AACC
2003 – Present	Faculty Senator (School of Medicine), University of Louisville
2002 – Present	College of American Pathologists, Inspector (number 1059583).
2003 – Present	Director, American Board for Clinical Chemistry and Toxicology
2007 - 2008	Chair, Research Division, Department of Pathology and Lab Medicine
2006 - 2008	Contributing Author, Laboratory Medicine Practice Guidelines in Pharmacogenetics. National Academy for Clinical Biochemistry
2005 - 2008	AACC Proteomics Division, Secretary and Newsletter Editor
2005 - 2008	Member, Therapeutic Drug Monitoring/Endocrinology Committee, (Special Chemistry) College of American Pathologists (CAP)
2005 - 2007	Member, Working Group on Urine Drug Testing in Clinical Laboratory, Clinical and Laboratory Standards Institute (CLSI)
2004	Chair, Workshops Committee, 9 th annual meeting of the International Therapeutic Monitoring and Clinical Toxicology, Louisville, KY 2005
2004	Chair, Fundraising Committee, 9 th annual meeting of the International Therapeutic Monitoring and Clinical Toxicology, Louisville, KY 2005
2003-2005	Chair elect, chair and past chair, Ohio Valley Section of AACC
2002 - 2004	Organizing committee. Lab medicine and OVS-AACC joint meeting
2002– 2002	Special judge for the AACC, Intel Science and Engineering Fair
2002 - 2004	National Academy of Clinical Biochemistry’s Fundraising committee.
1999 – 2002	Reviewer, for the AACC’s annual meetings abstract committee
2001 – 2001	Member, Awards Committee, Clinical Ligand Assay Society
2000 - 2003	Judge, AACC annual meetings student best poster contest
1999 – 2001	AACC’s Local Sections Affairs Committee in House of Delegates
1999 - 2000	Breath Alcohol Testing Task Force, TDM and Toxicology (AACC)
1999 - 2002	Chairman, Committee for Student Research Award, OVS-AACC
1998 - 2001	Delegate, Ohio Valley Section of the AACC
1997 - 1998	Education Chairman, Ohio Valley Section of the AACC
1993 - 1994	Clinical Ligand Assay Society, organizing committee
1990 - 1992	VCU Forbs Honors Committee
1990 - 1992	VCU Student Government Association
1990 - 1992	MCV International Student Advisory Committee
1987 - 1988	Phi Sigma (Biology) Committees

OTHER ACTIVITIES

1985 - 1991	Emergency Medical Technician, West End Volunteer Rescue Squad, Richmond, Virginia
-------------	---

EDITORIAL BOARDS

2009 – Present	Therapeutic Drug Monitoring
2005 – Present	Clinica Chemica Acta
2005 – Present	Clinical Proteomics
2007 – Present	Open Clinical Chemistry Letters

TEACHING

2001 – Present	Medical Students (Sophomore Pathology)
2003 – Present	Medical Students (Toxicology Elective)
2001 – Present	Clinical and Forensic Toxicology (Residents in Pathology; Fellows in Clinical Chemistry)
1996 – Present	Faculty, Clinical Chemistry Fellowship Program, University of Louisville School of Medicine

PATENTS

Disclosed Patents:

1. Urocortin III as a novel biomarker for heart failure
2. Urocortins for diagnosis of sleep apnea
3. Opioid Toxicity and Efficacy Computation (OpTEC)
4. A novel Biomarker for Pre-term Labor
5. Non-invasive biomarker for obstructive sleep apnea.

PUBLICATIONS- Peer Reviewed

BOOK CHAPTERS

1. **Jortani SA.** Theophylline and Caffeine. In: Clinical Chemistry (Theory, Analysis, correlation (3rd Edition). Kaplan L A and Pesce A J Eds. New York Mosby 1996: 1108-11.
2. **Jortani SA.** Theophylline. Methods of Analysis. Kaplan LA, Pesce AJ, eds. Evolve Resources for Clinical Chemistry: Theory, Analysis, and Correlation (3rd Edition). Kaplan L A and Pesce A J Eds. New York Mosby 2009.
3. Womack EP, Valdes Jr. R, **Jortani SA.** Liquid chromatography combined with Immunoassay as a reference method for analysis of digitalis. In: Recent advances in chromatographic techniques for therapeutic drug monitoring (Dasgupta A, editor) CRC Press. 2009.
4. Snow A, Gozal D, Valdes Jr. R, **Jortani SA.** Urinary proteins for the diagnosis of obstructive sleep apnea syndrome. In: Urinary Proteomics – AACCC Press. Rai A, Ed. 2010– In Press
5. Valdes RV, **Jortani SA,** Watson ID. Point-of-Care Testing and the Optimization of Pharmacotherapeutics. In: Point-of-Care Testing: Needs, Opportunity, and Innovation (3rd Edition). Price CP, St John A, Kricka LJ, Eds. Washington

JOURNAL ARTICLES

1. Edinboro LE, Jackson GF, **Jortani SA,** Balster RL. Determination of serum acetaminophen in emergency toxicology: evaluation of newer methods: Abbott TDx and second derivative ultraviolet spectrophotometry. Clinical Toxicology 1991;29:241-55.
2. Mansbach RS, Willetts J, **Jortani SA,** Balster RL. NMDA antagonists: Lack of antipunishment effect in squirrel monkeys. Pharmacology, Biochemistry & Behavior

1991;39:977-981.

3. **Jortani SA**, Willetts J, Balster RL. Systemic magnesium chloride administration fails to produce phencyclidine-like discriminative stimulus effects in rats. *Neuroscience Letters* 1992;135:136-8.
4. **Jortani SA**, Poklis. EMIT ETS-plus ethyl alcohol assay for the determination of ethanol in human serum and urine. *Journal of Analytical Toxicology* 1992;16:368-71.
5. **Jortani SA**, Poklis A. Evaluation of the Syva ETS-Plus urine drug and serum ethanol analyzer. *Journal of Analytical Toxicology* 1993;17:31-3.
6. **Jortani SA**, Poklis A. Evaluation of the Abbott ADx REA assay for determination of ethanol in human serum and urine. *Journal of Analytical Toxicology* 1993;17:307-9.
7. Poklis A, **Jortani SA**, Brown CS, Crooks CR. Response of the EMIT II amphetamine/methamphetamine assay to specimens collected following use of VICKS inhalers. *Journal of Analytical Toxicology* 1993;17:284-86.
8. **Jortani SA**, Poklis A. Determination of thioridazine enantiomers in human serum by sequential achiral and chiral high performance liquid chromatography. *Journal of Analytical Toxicology* 1993;17:374-77.
9. **Jortani SA**, Valentour J, Poliks A. Determination of the concentrations of thioridazine enantiomers in postmortem human tissues. *Forensic Sci. Intl.* 1993;64:165-70.
10. Mansbach, R.S., **Jortani, S.A.** and Balster, R.L. Antagonism of cocaine's reinforcing and discriminative stimulus effects by a-flupenthixol. *Exp. Clin. Psychopharmacol.* 2:3-12, 1994.
11. Poklis A, **Jortani SA**, Edinoboro LE, Saady JJ. Direct determination of benzoylecgonine in serum by EMIT d.a.u. Cocaine Metabolite Immunoassay. *Journal of Analytical Toxicology* 1994;18:419-22.
12. **Jortani SA**, Saady JJ, Poklis A. Improved detection of cocaine metabolite in urine from pregnant women and neonates by modified TDx assay. *Res. Comm. Substance Abuse* 1994;15:124-30.
13. Mansbach RS, **Jortani SA**, Balster RL. Discriminative stimulus effects of esteratic local anesthetics in squirrel monkeys. *Eur J of Pharmacol* 1995;274:167-73.
14. **Jortani SA**, Miller JJ, Valdes R Jr. Resolving clinically discrepant digoxin results: A case study involving multiple interferences. *Journal of Clinical Ligand Assay*, 1996;19:131-37.
15. Qazzaz HMAM, **Jortani SA**, Poole JM, Valdes R Jr. Evidence for presence of a reduced form of digoxin-like immunoreactive factor (Dihydro-DLIF) in mammalian tissues. *Clin Chem* 1996;42;1092-99.
16. Gupta A, Thorkelsson, **Jortani SA**, Valdes Jr R, Shemie S, Verjee Z, Joshi P. A case of non-digitalis cardiac glycoside intoxication. *Therapeutic Drug Monitoring* 1996;1977:711-14.

17. **Jortani SA**, Helm RA, Valdes R Jr. Inhibition of Na,K-ATPase by oleandrin and oleandrogenin and their detection by digoxin immunoassays. *Clin Chem* 1996;42:1654-58.
18. **Jortani SA**, Valdes R. Digoxin and related endogenous factors. *Critical Reviews in Clinical Laboratory Science* 1996;34:225-74.
19. Hobbs GA. **Jortani SA**. Valdes R Jr. Implementation of a successful on-call system in clinical chemistry. *Amer J of Clin Path.* 1997;108(5):556-63.
20. **Jortani SA**, Valdes R Jr. Antiarrhythmics in therapeutic drug monitoring and toxicology, an in-service training and continuing education program. 1997;18:259-76.
21. **Jortani SA**, Trepanier D, Yatscoff RW, Valdes R Jr. Convergence of three methods to resolve discrepant immunoassay digoxin results. *Clin Chem* 1997;43:1805-8.
22. Valdes R Jr., **Jortani SA**, Gheorgiade. Standards of laboratory practice: cardiac drug monitoring. *Clin Chem* 1998;44:1096-1109.
23. **Jortani SA**, Miller JJ, Helm RA, Johnson NA, Valdes R Jr. Suppression of immunoassay results by cross-reactivity. *Journal of Clinical Ligand Assay* 1997;20:177-79.
24. Valdes R Jr., **Jortani SA**. Monitoring of unbound digoxin in patients treated with anti-digoxin antigen-binding fragments: A model for the future? *Clin Chem* 1998;44:1883-1885.
25. Apple FS, Christenson RH, Valdes R Jr., Andriak AJ, Berg A, Dhu SH, Feng YJ, **Jortani SA**, Johnson NA, Koplen B, Mascotti K, Wu AHB. Simultaneous rapid measurement of whole blood myoglobin, creatine kinase MB, and cardiac troponin I by the Triage Cardiac Panel for detection of myocardial infarction. *Clin Chem* 1999;45:199-205.
26. **Jortani SA**, Pinar A, Johnson NA, Valdes R Jr. Validity of unbound digoxin measurements by immunoassays in presence of antidote (Digibind®). *Clinica Chemica Acta* 1999;283:159-169.
27. Valdes R Jr., **Jortani SA**. Standardizing utilization of biomarkers in diagnosis and management of acute cardiac syndromes. *Clinica Chemica Acta* 1999;284:135-140.
28. **Jortani SA**. Point-of-care testing for alcohol. An in-service training and continuing education program. *Therapeutic Drug Monitoring and Toxicology* 2000;21(5):121-6.
29. **Jortani SA**, Snyder J, Valdes R Jr. Clinical laboratory's role in managing terrorism with chemical and biological agents. *Clin Chem (Invited Review)*, 2000;46:1883-1893.
30. **Jortani SA**, Valdes R Jr. The difference between digoxin and digitoxin is more than an *it*. *Clinical Toxicology News Letter*. American Association for Clinical Chemistry, 2000:DEC;2-3.
31. **Jortani SA**. Alcohol testing near the patient. *Advance Laboratory*, 2001;10:10-11.
32. Valdes R Jr., **Jortani SA**. The current assessment of qualitative and quantitative point-of-care delivery of cardiac markers. In: *Markers in Cardiology: Current and Future Clinical*

- Applications. Adams JE III, Apple FS, Jaffe AS, WU AHB, eds. Armonk, NY: Futura Publishing Company, Inc. 2001:35-46.
33. **Jortani SA**, Valdes R Jr. Mammalian cardenolides as biomarkers in congestive heart failure. *Cardiovascular Toxicology*. 2001;1:165-170.
 34. **Jortani SA**, Snyder J, Valdes Jr R. Role of clinical laboratory in dealing with bioterrorism. *J of Isfahan Medical Council* 2002;12:32-38.
 35. Valdes R Jr., **Jortani SA**. Unexpected suppression of immunoassay results by cross-reactivity: now a demonstrated cause for concern. *Clinical Chemistry*. 2002;48(3):405-6.
 36. Keeling KL, Linder MW, Bukaveckas BL, **Jortani SA**, and Valdes R Jr. Rigorous Approach For Investigation of Unexpected Phenytoin Toxicity. *J Clin Ligand Assay* 2003;26:19-24.
 37. Barrueto F Jr, **Jortani SA**, Valdes R Jr, Hoffman RS, Nelson LS. Cardioactive steroid poisoning from an herbal cleansing preparation. *Ann Emerg Med*. 2003 Mar;41(3):396-399.
 38. Valdes R Jr, Linder MW, **Jortani SA**. What is next in pharmacogenomics? – Translating it into clinical practice. *Pharmacogenomics* 2003;4:499-505.
 39. **Jortani SA**. Immunoassays in clinical and forensic toxicology. *J Clin Ligand Assay* 2003;26:3-4.
 40. Elbeik T, Surtihadi J, Destree M, Gorlin J, Holodniy M, **Jortani SA**, Kuramoto K, Ng V, Valdes Jr R, Valsamakis A, Terrault N. Multicenter Evaluation of the Performance Characteristics of the Bayer VERSANT HCV RNA 3.0 Assay (bDNA), *Journal of Clinical Microbiology* 2004;42: 563-569.
 41. **Jortani SA**, Pradbu S, Valdes R Jr. Development of biomarkers in congestive heart failure. *Clinical Chemistry*. (Invited Review) 2004; 50; 265-278.
 42. **Jortani SA**, Pugia MJ, Elin RJ, Thomas M, Womack EP, Cast T, Valdes R Jr. Sensitive Noninvasive Marker for the Diagnosis of Probable Bacterial or Viral Infection. *Journal of Clinical lab Analysis* 2004;18:289-295.
 43. Pugia MJ, Sommer R, Corey P, Anderson L, Gleason S, **Jortani SA**, Elin RJ, Gopual DL, Valdes Jr.R, Lott JA. The uristatin dipstick is useful in distinguishing upper respiratory from urinary tract infections. *Clinica Chemica Acta*. 2004;341:73-81
 44. Chaturvedi K, **Jortani SA**. Consequences of adverse drug events/reactions in health care. *Louisville Medicine* 2004;51:473-478.
 45. **Jortani SA**. *Toxicogenomics: Principles and Applications*. Hisham K. Hamadeh and Cynthia A. Afshari. Hoboken, NJ: John Wiley and Sons, Inc., 361 pp., \$64.95, hardcover. ISBN 0-417-43417-5. *Clin Chem* 2005;51:1568.
 46. Zhu Y, Valdes R Jr, **Jortani SA**. Application of bioaffinity mass spectrometry for analysis of ligands. *Ther Drug Monitor* 2005;27(6):694-699.

47. Shah ZA, **Jortani SA**, Tauman R, Valdes R Jr, Gozal D. Serum proteomic patterns associated with sleep-disordered breathing in children. *Pediatr Res*. 2006 Mar;59(3):466-70).
48. Hortin GL, **Jortani SA**, Ritchie Jr. JC, Valdes Jr. RV, Chan DW. Proteomics: A New Diagnostic Frontier. *Clin Chem* 2006; 52: 7.
49. Puglia MJ, **Jortani SA**, Basu M, Sommer R, Kuo HH, Murphy S, Williamson D, Vranish J, Boyle PJ, Budzinski D, Valdes R Jr, Basu SC. Immunological evaluation of urinary trypsin inhibitors in blood and urine: Role of N- & O-linked glycoproteins. *Glycoconj J*. 2007;24:5-15.
50. Zhu Y, Valdes R Jr, Simmons CQ, Linder MW, Puglia MJ, **Jortani SA**. Analysis of ligand binding by bioaffinity mass spectrometry. *Clinica Chimica Acta* 2006;371(1-2):71-8.
51. Thomas A., Tourassi GD, Elmaghraby AS, Valdes Jr R, **Jortani SA**. Data Mining In Proteomic Mass Spectrometry. *Clin Proteomics* 2007;2:13-22.
52. Franke DDH, **Jortani SA**. Importance of using gas chromatography for diagnosis of patients poisoned with multiple alcohols. *Clinica Chimica Acta* 2007;380(1-2):241-2.
53. Armbruster DA, Dasgupta A., Earley RJ, **Jortani SA**, Markus W, Rheinheimer DW. Toxicology and Drug Testing in the Clinical Laboratory; Approved Guidelines – Second Edition. Clinical and Laboratory Standards Institute 2007;27 (15):C52-A2.
54. Mukhopadhyay S, **Jortani SA**, Valdes Jr R, Simmons CQ, Sullivan ED, Miller RD, Summersgill JD. Protein Expression of Analysis *Chlamydia pneumoniae* Persistence by Combined SELDI TOF-MS and 2D PAGE. *Clinical Proteomics* 2007; 2(3-4), 205-216.
55. Puglia MJ, Valdes R Jr, **Jortani SA**. Bikunin (Urinary Trypsin Inhibitors): Structure, Biological Relevance and Measurement. *Advances in Clinical Chemistry*. 2007;44:223-45.
56. Miles TP, Hanson S, Kidd L, Connor A, **Jortani SA**. Sensitivity Analysis of Self-Identified Race and Ethnicity (SIRE): Screening for Single Nucleotide Polymorphisms. *Nature Preceding*. 2008; <http://precedings.nature.com/search?scope=all&query=jortani>
57. Ingram DM, Bosse GM, Womack Jr EP, **Jortani SA**. Evaluation of a urine screen for acetaminophen. *Journal of Medical Toxicology* 2008;4:96-100.
58. Reynolds KK, Ramey-Hartung B, **Jortani SA**. The value of CYP2D6 and OPRM1 pharmacogenetics testing for opioids. *Clin Lab Med* 2008;28:581-598.
59. Franke DDH, Davis EG, Woods DR, Johnson RK, Miller FB, Franklin GA, **Jortani SA**. Catastrophic Gastrointestinal Injury Due to Battery Acid Ingestion. *Journal of Emergency Medicine*. 2009. Corrected proof On-line Pre-published Dec. 2008
60. Steele PS, Franke DDH, Linder MW, Valdes Jr. R, **Jortani SA**. Proteomic Study of Hepatic Nuclear Extracts in an Adaptive Acetaminophen Tolerance Model. *Clin Proteomics*, 2009;5:69-74.

61. Puglia, MJ, Franke DHD, Barnes SL, Zerchera A, Brocka D, Foltz M, Valdes Jr. R, **Jortani SA**. Adiponectin Receptor-1 C-Terminal Fragment (CTF) in Plasma: Putative Biomarker for Diabetes. *Clinical Proteomics* 2009;5:156-62.
62. Gozal D, **Jortani SA**, Snow A, Kheirandish-Gozal, L, Bhattacharjee R, Kim K, Sans Capdevila O. Two-dimensional Differential in-gel Electrophoresis Proteomic Approaches Reveal Urine Candidate Biomarkers in Pediatric Obstructive Sleep Apnea. *American Journal of Respiratory and Critical Care Medicine* 2009;180(12):1253-61.
63. El-Mallakh RS, Stoddard M, **Jortani SA**, El-Masri MA, Sephton S, Valdes Jr. R. Aberrant regulation of endogenous ouabain-like factor in bipolar subjects. *Psychiatry Research* 2009 (In Press).
64. **Jortani, SA**, Loyd GE, Stauble E. Pain Management – What Role Can Pharmacogenetics Play? *Clinical Laboratory News*. November 2009:8-10.
65. **Jortani, SA**, Wong S. Laboratory analysis and application of pharmacogenetics to clinical practice: Ancillary applications: drug prescription/dispensing and forensics. *The National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines*. (http://www.aacc.org/members/nacb/LMPG/OnlineGuide/PublishedGuidelines/LAACCP/Documents/PGx_Chapter8.pdf). 2010; March:35-38.

PRESENTATIONS AND ABSTRACTS

1. **Jortani SA**, Gbadebo DT, Kimborough TD, Mills RR. Cuticle formation during ecdysis by the American cockroach. *Virginia Journal of Science* 1988;39(2):115.
2. **Jortani SA**, Willetts, Balster RL. Hypermagnesemia fails to produce PCP-like discriminative stimulus effects in rats. *Virginia Journal of Science* 1989;40(2):144.
3. **Jortani SA**, Edinboro LE, Jackson GF, Poklis A. Determination of serum acetaminophen in emergency toxicology evaluation of newer methods: Abbott TDx and second derivative ultraviolet spectrophotometry. *American Academy of Forensic Sciences* February, 1991; Anaheim, CA.
4. Poklis A, **Jortani SA**. Evaluation of ETS Plus Ethyl Alcohol assay for determination of ethanol in serum and urine. *American Academy of Forensic Sciences* 1991; February, 1991; Anaheim, CA.
5. Poklis A, **Jortani SA**, Edinboro LE, Saady JJ. Detection of opiates and cocaine metabolites in serum by direct analysis by EMIT-d.a.u. assays. Annual meeting of Society of Forensic Toxicologists September, 1991; Montreal, Quebec.
6. **Jortani SA**, Gbadebo DT, Kimborough TD, Mills RR. Cuticle formation during ecdysis by the American cockroach. *Virginia Journal of Science* 1988;39(2):115.
7. **Jortani SA**, Willetts, Balster RL. Hypermagnesemia fails to produce PCP-like discriminative stimulus effects in rats. *Virginia Journal of Science* 1989;40(2):144.

8. **Jortani SA**, Edinboro LE, Jackson GF, Poklis A. Determination of serum acetaminophen in emergency toxicology evaluation of newer methods: Abbott TDx and second derivative ultraviolet spectrophotometry. American Academy of Forensic Sciences February, 1991; Anaheim, CA.
9. Poklis A, **Jortani SA**. Evaluation of ETS Plus Ethyl Alcohol assay for determination of ethanol in serum and urine. American Academy of Forensic Sciences 1991; February, 1991; Anaheim, CA.
10. Poklis A, **Jortani SA**, Edinboro LE, Saady JJ. Detection of opiates and cocaine metabolites in serum by direct analysis by EMIT-d.a.u. assays. Annual meeting of Society of Forensic Toxicologists September, 1991; Montreal, Quebec.
11. Poklis A, **Jortani SA**, Brown CS, Crooks CR. Response of the EMIT II Amphetamine/Methamphetamine assay to specimens collected following use of Vicks inhalers. Annual meeting of the Society of Forensic Toxicologists October, 1992; Romwell, CT.
12. **Jortani SA**, Edinboro LE, Jackson GF, Polkis A. Determination of serum acetaminophen in emergency toxicology. 4th Iranian Pharmaceutical Congress October, 1992; Tabriz, Iran. (by invitation).
13. **Jortani SA**. Effective use of immunoassays for clinical toxicology (round-table presentation). Annual meeting of Clinical Ligand Assay Society May, 1995; Toronto, Canada).
14. Poole JM, **Jortani SA**, Valdes RA Jr. R. Separation of digoxin and dihydrodigoxin by HPLC with improved detection by two immunoassays. Annual meeting of the Clinical Ligand Assay Society May, 1995; Toronto, Canada.
15. **Jortani SA**, Helm RA, Valdes R Jr. A rigorous approach for resolving discrepancies in serum digoxin results. Annual meeting of the Clinical Ligand Assay Society May, 1995; Toronto, Canada.
16. Qazzaz HMA, Poole JM, **Jortani SA**, Valdes RM, Valdes R Jr. Presence of an endogenous dihydro-digoxin-like immunoreactive factor (Dihydro-DLIF) in adrenal cortex. Annual and joint meeting of the ASBMB/DBC-ACS May 1995; San Francisco, California. FASEB Journal; 9(6) A1368.
17. Qazzaz HMA, Poole JM, **Jortani SA**, Valdes Jr R. Evidence for existence of an endogenous dihydrodigoxin-like immunoreactive factor (dihydro-DLIF) in mammalian tissue. Annual meeting of the American Association for Clinical Chemistry July, 1995 Anaheim, CA. Clin Chem ;41:(S6) S44.
18. **Jortani SA**, Straub RW, Qazzaz HMA, Valdes Jr. R. Generation of digoxin-like immunoreactive factors from metabolism of dihydrodigoxin by bovine adrenal cortex microsomes. Annual meeting of the American Association for Clinical Chemistry, July, 1995; Anaheim, CA Clin Chem; 41(S6) S45. "First Place Winner in Student Poster Contest".

19. **Jortani SA**, Helm RA, Valdes Jr R, Gupta A, Joshi P, Verjee Z. Discovery of oleander poisoning in a child by digoxin immunoassays and reversed-phase HPLC. 1995 Annual meeting of the Society of Forensic Toxicologists.
20. **Jortani SA**, Valdes Jr R. Coping with Discrepant Digoxin Results. A Case Study Approach. Fourth International Therapeutic Drug Monitoring and Clinical Toxicology, September 1995; Vienna, Austria.
21. **Jortani SA**, Valdes Jr R. Latest on Digoxin Monitoring. Medical School of Isfahan, Physicians continuing education program, September, 1995; Isfahan, Iran.
22. **Jortani SA**, Valdes Jr R. Biochemical Markers for Detection of Myocardial Infarction. Medical School of Isfahan Physicians continuing education program, September, 1995; Isfahan, Iran.
23. **Jortani SA**. Interpretation and Discrepancies in Serum Digoxin Results. Ohio Society for Clinical Laboratory Science. April, 1996; Toledo, Ohio.
24. **Jortani SA**, Miller JJ, Helm RA, Valdes Jr R. 1996. Unexpected suppression of digoxin values caused by DLIF. Clin Chem 1996;42:(S6) S124.
25. **Jortani SA**, Helm RA, Valdes Jr R. Two cases in which polar digoxin metabolites explain discrepancy in digoxin immunoassay results. Clin Chem; 1996;42 (S6) S212.
26. **Jortani SA**, Broadbent JE, Miller JJ, Stone MA, Hooker EA, Wagner R, Bolli R, Valdes Jr R. 1996. Unexplained concentrations of cardiac troponin I in patients ruled out for acute myocardial infarction (AMI). Clin Chem 1996;42 (S6) S245.
27. **Jortani SA**, Helm RA, Valdes Jr R. 1996. CNS toxicity caused by oleander and digoxin may be mediated by poisoning the sodium pump. Annual meeting of the Association for the Clinical Laboratory Sciences, Louisville, KY.
28. **Jortani SA**, Trepanier D, Yatscoff RW, Valdes R Jr. 1997. Convergence of three methods to resolve discrepant immunoassay digitoxin results. 29th annual Oak Ridge Conference, St. Louis, MO.
29. **Jortani SA**, Helm RA, Johnson NA, Valdes R Jr. 1997. Suspected polar metabolites of digitoxin account for discrepancy in digitoxin immunoassay results. 49th annual meeting of the American Association for Clinical Chemistry, Atlanta, GA.
30. **Jortani SA**, Pinar A, Johnson NA, Valdes R Jr. 1998. Evaluation of unbound digoxin measurements in the presence of antidote (Digibind) by immunoassays. 50th annual meeting of the American Association for Clinical Chemistry, Chicago, IL.
31. **Jortani SA**, Johnson NA, Brown GL, Valdes R Jr. 1998. Decreased recovery of digoxin in serum collected from pregnant women. Clin Chem 1998;44:A87.
32. **Jortani SA**, Falamarzian M, Varshosaz J, Ghafghazi T, Raisi A. Predicting bioavailability of different tablet formulations of aminophylline and theophylline by assessing their dissolution rates. Clin Chem 1999;S434:A122.

33. **Jortani SA**, Johnson NA, Valdes Jr. Performance of the valproic acid assay on Beckman Coulter's IMMAGE[®] immunochemistry system. Clin Chem 1999;S433:A122.
34. **Jortani SA**, Harrison H, Johnson NA, Subudhi J, Valdes Jr. Monoclonal gammopathy associated with an anomalous digoxin measurement. Clin Chem 2000;46:A38.
35. **Jortani SA**, Practical and legal considerations in selecting and using expert witnesses, and pursuing or defending a *Daubert* challenge. The Litigation Section of the Louisville Bar Association and the University of Louisville Brandeis School of Law. April 2000.
36. **Jortani SA**, Breath Alcohol Testing. American Association for Clinical Chemistry's Expert of the Month On-Line. http://www.aacc.org/access/poct_alcohol/index.stm. July 2000.
37. **Jortani SA**, Valdes R Jr. Mechanisms of toxicity by herbal medicines. 1st International Meeting of Traditional Medicine. Tehran, Iran. November 2000.
38. Keeling KL, **Jortani SA**, Linder MW, Valdes Jr. R. Prolonged elimination half-life of phenytoin in an elderly patient also on Celecoxib. Clin Chem 2002;48:B44.
39. Keeling KL, **Jortani SA**, Womack PW, Valdes Jr. R. Measurement of endogenous dihydroouabain-like factor (Dh-OLF) in heart failure patients. Clin chem. 2003;49:A69.
40. Y. Zhu, **Jortani SA**, Simmons CQ, Valdes Jr. R. A novel antibody screening technique using protein analysis by SELDI-TOF mass Spectrometry. Clin Chem 2004;50:A33.
41. Ahmed ZA, Qazzaz HMH, **Jortani SA**, Valdes Jr. R. Detection of ouabain-like factor (OLF)-binding protein from human plasma using mass spectrometry technology Clin Chem 2004;50:A99.
42. Keeling KL, **Jortani SA**, Steimer W, Valdes Jr. R. Importance of evaluating the effects of polar metabolites on digoxin immunoassays. Clin Chem 2004;50:A133.
43. Shah ZA, Gozal D, Krishna J, Tauman R, Goldbart, Valdes. Jr R, **Jortani SA** Serum proteomic pattern associated with obstructive sleep apnea (OSA) in children. American journal of respiratory and critical care medicine. 2004: 169: A715.
44. **Jortani SA**, Steimer W, Reynolds KK, Womack¹, Barnes W, Brookhart PP, Doss RC, Valdes R Jr. Demonstration of the mechanism for phenomenon of suppression of immunoassay results caused by cross-reactivity. Ther Drug Monit 2005;27:223.
45. Ingram D, Bosse GM, Rahbar M, Womack EP, **Jortani SA**. Evaluation of a new 15-minute qualitative urine acetaminophen test. Ther Drug Monit 2005;27:223.
46. Wong SHY, Jin, Shi, Gock, Jentzen, Schur, Frolov, Rogalska, Cuyahoga, Jenkins, Balraj, Helper, Isenschmid, Schmidt, Kerrigan, Winecker, Roper-Miller, McIntyre, Karch Lemos, Langman, Couper, Logan, Gordan, Moody, **Jortani SA**. Pharmacogenomics as an adjunct of molecular autopsy – A multi-center study for methadone death certification: Preliminary findings of data acquisition and multiplex genotyping CYP2D6, 2C9, 2C19, 3A4, 3A5 by Pyrosequencing. Ther Drug Monit 2005;27:260.

47. Mukhopadhyay S, **Jortani SA**, Valdes Jr R, Simmons CQ, Sullivan ED, Miller RD, Summersgill JD. Comparative proteomic expression analysis by SELDI TOF-MS and 2D PAGE of *Chlamydia pneumoniae* persistence induced by interferon-gamma. ASM 2005.
48. Dahlen J, Bishop J, Bruce P, Kempner C, McPherson P, Valkris G, Cuechler J, Ingram D, Bosse G, Rahbar M, Womack EP, **Jortani SA**. A rapid point-of-care immunoassay system for the detection of acetaminophen (APAP) in urine. Clin Chem 2005;51:A259.
49. **Jortani SA**, Reynolds KK, Steimer W, Womack EP, Barnes W, Brookhart PP, Eng K, Doss RC, Valdes Jr R. Evaluation of a Modified Protocol to Eliminate Suppression of Immunoassay Results Caused by Cross-reactivity. Clin Chem 2005;51:A47.
50. Makkar A, Banchs J, Hauck MA, Siddiqui TS, **Jortani SA**, Valdes Jr. R, Koenig SC, Mitchell ME, Tomita-Mitchell A, Prabhu SD. Identification of Genetic Variants of the Tumor Necrosis Factor Receptor 2 Gene (TNFRSF1B) in Patients with Heart Failure. American Heart Association' Scientific Sessions, 2006.
51. **Jortani SA**, Franke DD, Hernberger M, Valdes Jr. R, Linder MW. Differential expression of transcriptional regulatory proteins is associated with acquired tolerance to acetaminophen induced toxicity. Clin Chem 2006;52:A62-3.
52. Franke D., Brown G., **Jortani SA**. Laboratory Evaluation of A Patient Poisoned With Multiple Alcohols: Potential Pitfall Of Using Enzymatic Assays For Ethanol. J Clin Lig Assay 2007, in press.
53. Grant SN, Womack Jr., EP, Prabhu PD, Valdes Jr., **Jortani SA**. Urocortin III in Cardiovascular Disease. Research Louisville, October, 2006.
54. Franke DD, Valdes Jr., **Jortani SA**. A method for profiling cross-reactivities of cardiac troponin I antibodies used in current diagnostic assays. Clin Chem 2007;53:A19..
55. Franke DD, Pugia JM, Valdes Jr., **Jortani SA**. Characterizing antibody cross-reactivity of adiponectin receptor fragments in human plasma by immuno-mass spectrometry. Clin Chem 2007;53:A76.
56. Steele PS, **Jortani SA**, Franke DD, Valdes Jr., Linder MW. Analysis of nucleic acid-protein interactions using competitive binding and mass spectrometry. Clin Chem 2007;53:A82.
57. Herrnberger MR, Reynolds K, **Jortani SA**, Linder MW, Valdes Jr. Reproducibility of the NanoChip® 400 CYP2C9/VKORC1 RUO genotyping panel. Clin Chem 2007;53:A154.
58. Womack EP, Semegen SA, **Jortani SA**, Valdes Jr., R. Uzara Promotes Cell Death in Lung and Breast Cancer Cells. Clin Chem 2008;45:A134.
59. **Jortani SA**, Womack EP, Vallen-Thompson M, Fan J, Volkir SP, Schultz K, Wu AHB. Clinical Performance Evaluation of the CLINITEK Microalbumin 9 Reagent Strip: A New Urinalysis Dry Reagent Strip. Diabetolog 2008;51 (suppl1):S483.
60. Barnes SL, Womack EP, Bon Homme M, Tucker WW, Valdes Jr R, **Jortani SA**. Plasma

Concentrations of Adiponectin Hormone in Type 1 and Type 2 Diabetes. Clin Chem 2009;55:A191.

61. Bon Homme M, Malek SJ, **Jortani SA**. Convergence of Lateral Flow, ELISA and Western-Blot Techniques in Detection of Soluble Peanut Proteins. Clin Chem 2009;55:A266.
62. Tucker WW, Parker J, Womack EP, Holland B, Bishop J, Gamboa A, Chanchico R, Bosse GM, **Jortani SA**. An Alternative Approach for Detection of Acetylsalicylic Acid Ingestion. Clin Chem 2009;55:A265.

NATIONAL INSTITUTE FOR DRUG ABUSE CONTRACT REPORTS – Non-Peer Reviewed

1. Mansbach RS, Balster RL, **Jortani SA**. Cocaine discrimination in squirrel monkeys: Evaluation of mazindol. 1991. Report DD91.3 submitted to the National Institute of Drug Abuse from the Department of Pharmacology and Toxicology, Medical College of Virginia, Virginia Commonwealth University.
2. Mansbach RS, Balster RL, **Jortani SA**, Soehngen E. Cocaine discrimination in squirrel monkeys: Evaluation of Flupenthixol. 1991. Report DD92.10 submitted to the National Institute of Drug Abuse from the Department of Pharmacology and Toxicology, Medical College of Virginia, Virginia Commonwealth University.
3. Mansbach RS, Balster RD, **Jortani SA**, Soehngen E. Cocaine discrimination in squirrel monkeys: Evaluation of (+)-AJ 76. 1992. Report DD92.9 submitted to the National Institute of Drug Abuse from the Department of Pharmacology and Toxicology, Medical College of Virginia, Virginia Commonwealth University.
4. Mansbach RS, Balster RL, **Jortani SA**. Cocaine discrimination in squirrel monkeys: Evaluation of N0923. 1992. Report DD92.17 submitted to the National Institute of Drug Abuse from the Department of Pharmacology and Toxicology, Medical College of Virginia, Virginia Commonwealth University.
5. Mansbach RS, Balster RL, **Jortani SA**. Cocaine discrimination in squirrel monkeys: Evaluation of SCH 39166. 1992. Report DD92.16 submitted to the National Institute of Drug Abuse from the Department of Pharmacology and Toxicology, Medical College of Virginia, Virginia Commonwealth University.
6. Mansbach RS, Balster RL, **Jortani SA**. Cocaine discrimination in squirrel monkeys: Evaluation of Buspirone. 1992. Report DD92.22 submitted to the National Institute of Drug Abuse from the Department of Pharmacology and Toxicology, Medical College of Virginia, Virginia Commonwealth University.
7. Mansbach RS, Balster RL, **Jortani SA**. Cocaine discrimination in squirrel monkeys: Evaluation of SDW-2. 1992. Report DD92.33 submitted to the National Institute of Drug Abuse from the Department of Pharmacology and Toxicology, Medical College of Virginia, Virginia Commonwealth University.

WORKSHOPS & SEMINARS

1. Basic mechanisms of neuronal excitability and epilepsy. Society of Neuroscience (Central Virginia Chapter), March 1992. Richmond, Virginia.
2. Immunoassays: Current practice. The Ohio Valley Section/AACC, January, 1994. Cincinnati, Ohio.
3. Concepts and practice in the evaluation of laboratory methods. Clinical Ligand Assay Society, January 1994. Indianapolis, Indiana.
4. Serum markers for diagnosis and monitoring of myocardial injury. Clinical Ligand Assay Society, May 1995. Toronto, Canada.
5. Wong SHY, Jortani SA, Eap CB, Moody D. Methadone – clinical toxicology and pharmacogenomics. Workshop presentation. International Therapeutic Drug Monitoring and Clinical Toxicology Congress. Louisville, KY April 2005.
6. Chemical Exposures. AACC Audio Conference. April, 2007.
7. Jortani, SA, Stauble S, Tasch B. Pain Management. International Association for Therapeutic Monitoring and Clinical Toxicology. Annual Meeting Workshop. 2009, Montreal, Canada.

LECTURESHIPS (from 2001)

1. Jortani SA, Valdes R Jr. Status of biomarkers for congestive heart failure. Association of Clinical Scientists annual meeting. Chapel Hill, North Carolina, May 2001.
2. Jortani SA. Neurotoxicity of organophosphates. International Congress of Therapeutic Drug Monitoring and Clinical Toxicology. Washington DC, September 2001.
3. Jortani SA. Mechanisms of toxicity caused by herbal medicines. International Congress of Therapeutic Drug Monitoring and Clinical Toxicology. Washington DC, September 2001.
4. Jortani SA. Basics of Forensic Toxicology. State Medical Examiner Lecture Series. Kentucky, June 2001.
5. Jortani SA. Postmortem redistribution of drugs. State Medical Examiner Lecture Series. Kentucky, August 2001.
6. Jortani SA. Laboratory's role in managing chemical terrorism. State Medical Examiner Lecture Series. Kentucky, November 2001.
7. Jortani SA. Poisonings due to herbal medicines. Clinical Toxicology Regional Meeting. Norton Healthcare, Louisville, Kentucky, November 2001.

8. Jortani SA, RJ Elin, M Thomas, EP Womack, MJ Pugia, R Valdes Jr. Uristatin as an aid in diagnosis of bacterial infection. International Federation for Clinical Chemistry, Kyoto, Japan, October 2002.
9. Jortani SA. Poisonings by herbal medicines. Annual meeting of the Mexican Association for clinical biochemistry. Morelia, Mexico, March 2002.
10. Jortani SA, Valdes Jr., R. Molecular basis linking pharmacology to medical genetics. Annual meeting of the Mexican Association for clinical biochemistry. Morelia, Mexico, March 2002.
11. Jortani SA, Linder MW. Pharmacogenetics: Clinical applications now and in the future. Annual meeting of the Mexican Association for clinical biochemistry. Morelia, Mexico, March 2002.
12. Jortani SA. Postmortem redistribution of drugs. Legal and Medicine. Isfahan Medical School, Iran, 2002 (May issue):161-162.
13. Jortani SA. Expert witness in the court of law: Daubert challenge. Legal and Medicine. Isfahan Medical School, Iran, 2002 (May issue):73-74.
14. Jortani SA. Practical challenges in the use of pharmacogenomics and proteomics in forensic toxicology. Society of Forensic Toxicologists. Workshop. Dearborn, Michigan October 2002.
15. Jortani SA. Free hormone measurements. Lab Medicine and OVS Joint Symposium. Louisville, KY 2002.
16. Jortani SA. Surface enhance laser desorption ionization mass spectrometry. IMD3 fall meeting. November 2002.
17. Jortani SA. Biological and Chemical Terrorism – American Association of Forensic Sciences. Chicago 2003.
18. Jortani SA. Presenting Faculty, the Edutrack for the Use of Mass Spectrometry in Clinical Laboratory. American Association for Clinical Chemistry (AACC). 2003.
19. Jortani SA. A novel antibody screening technique using protein analysis by SELDI-TOF mass Spectrometry. Bayer Diagnostics, Elkhart, IN 2004
20. Jortani SA. Discovery of Biomarkers in disease. ASCP teleconference. June 2004.
21. Jortani SA. Ibagaine and GHB. Isfahan Medical School, Iran, 2004
22. Jortani SA. Unexpected Phenytoin toxicity. Isfahan Medical School, Iran, 2004
23. Katchman Award Ceremony Honoring Saeed Jortani, Ph.D. The Katchman Award of the OVS-AACC acknowledges outstanding service to the OVS and contributions in the field of Clinical Chemistry. Lab Symposium, 2004

24. Jortani SA, Steimer W, Reynolds KK, Womack1, Barnes W, Brookhart PP, Doss RC, Valdes R Jr. Demonstration of the mechanism for phenomenon of suppression of immunoassay results caused by cross-reactivity. (Abstract selected for oral presentation) Ther Drug Monit 2005;27:223.
25. Jortani SA. Evaluation of a new 15-minute qualitative urine acetaminophen test. BioSite 2005.
26. Jortani SA. Biomarker discovery by mass spectrometry. Symposium presentation. International Therapeutic Drug Monitoring and Clinical Toxicology Congress. Louisville, KY April 2005.
27. Jortani SA, Valdes Jr R. Evaluation of a Modified Protocol to Eliminate Suppression of Immunoassay Results Caused by Cross-reactivity. Abbott Diagnostics 2005.
28. Jortani SA. Stimulants: Cocaine and MDMA. Isfahan Medical School, Iran, 2005
29. Jortani, SA. Therapeutic treatment of opiate addiction: Methadone and buprionorphine. Isfahan Medical School, Iran, 2005
30. Jortani, SA. Biomarkers for acute coronary syndromes and heart failure. Isfahan Medical School, Iran, 2005.
31. Jortani SA. Biomarkers for Sleep Apnea. Clinical Proteomics Edutrack. AACC Annual Meeting, Orlando FL 2005. Jortani, SA. Proteomics, A new Frontier. Presenting Faculty and Organizing Committee. Washington DC, October 2005.
32. Jortani SA. Automation in advanced technology for genomics and proteomics. International Conference on Advanced Technology. Hongzhou, China November 2005.
33. Jortani, SA. LMPG's for Pharmacogenetics by the NACB: Ancillary Applications, July, American Association for Clinical Chemistry Annual meeting, Chicago, July, 2006.
34. Jortani SA and Hanlon J. Alternative Medicines in Elderly Patients. 6th Annual Geriatrics Healthcare Symposium, Louisville, 2006.
35. Jortani SA. Finding Biomarkers through Proteomic Mass Spectrometry. Institute for Molecular Discovery Design and Diversity. Louisville, 2006.
36. Jortani SA. Mechanisms of Toxicity Caused by Herbal Medicines. Jewish Hospital and University of Louisville Primary Care Grand Rounds. Louisville, March 2006.
37. Jortani SA. Ancillary Considerations for PGx Testing: Forensics, Pharmaceutical Dispensing et al. American Association for Clinical Chemistry (AACC) annual meeting, Chicago 2006.
38. Jortani, SA. Use of Mass Spectrometry in Protein Discovery and Identification. Workshop organizer and presenter. The 32nd International Meeting of Clinical Ligand Assay Society. Louisville, May 2006.

39. Jortani, SA. The Emerging Field of Pharmacogenetics. Department of Pathology Grand Rounds, University of New Mexico. December 2006.
40. Jortani SA. Postmortem Drug Interpretations. Anatomic and Clinical Pathology Update. Louisville, KY. May 2007.
41. Jortani SA. (Workshop Co-Chair and Presenter). Methadone: Update on Clinical Pharmacology, Clinical and Forensic Toxicology and Pharmacogenomics. International Therapeutic Drug Monitoring and Clinical Toxicology. Nice, France. September 2007.
42. Jortani SA. Acetaminophen screening: Technical overview and practical experiences with a new rapid, qualitative urine assay. Industrial Workshop Presentation. International Therapeutic Drug Monitoring and Clinical Toxicology. Nice, France. September 2007.
43. Jortani SA. DNA Transcriptional Factor Interaction Mapping by Proteomic Mass-Spectrometry. AACCC's Proteomics Conference. Seattle, WA (May, 2008).
44. Jortani SA. Adiponectin receptor fragments in metabolic syndrome and NASH. Digestive Disease Research Center, Tehran University of Medical Sciences. Iran. June, 2008.
45. Jortani SA. Clinical Drug Screening. Shariati Hospital. Tehran, Iran. Tehran, Iran. June, 2008.
46. Jortani S.A. Novel Computational Tools for Translating Genomic Biomarkers into Clinical Practice: Case for Warfarin. Cambridge Healthtech Biomarker Series-Biomarker Discovery Summit. Philadelphia. September 2008.
47. Jortani S.A. Application of Pharmacogenetics in Pain Management. A Lunch-n-Learn sponsored by Roche and OraSure Technologies at the Society of Forensic Toxicologists (SOFT) Conference. Phoenix, AZ. October 2008.
48. Jortani S.A. Clinical Pharmacogenetics Testing: Applications in Anticoagulation and Pain Management. Florida Section of the AACCC. Memorial Regional Hospital. December 2008.
49. Jortani S.A. Gender difference in adiponectin (obesity and diabetes). Epigenetics conference. Advancing Women's Health Group at U of L. December 2008.
50. Jortani S.A. Proteomics and Toxicology: Interaction Mapping. Clinical Laboratory and Analytical Sciences. Annual Meeting. Boston, MA 2009.
51. Jortani S.A. Role of Clinical Chemists in Translating Novel Biomarkers into Clinical Practice. National Cancer Institute (NIH) Annual Meeting for Clinical Proteomics Technologies in Cancer. Bethesda, 2009.
52. Jortani S.A. Role of pharmacogenetics in pain management. International Association for Therapeutic Drug Monitoring and Clinical Toxicology. Annual Meeting. Montreal, 2009.